These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 25432720)

  • 21. Nosology of Parkinson's disease: looking for the way out of a quagmire.
    Forman MS; Lee VM; Trojanowski JQ
    Neuron; 2005 Aug; 47(4):479-82. PubMed ID: 16102530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [What can we learn from genes responsible for familial forms of Parkinson's disease?].
    Brice A
    Bull Acad Natl Med; 2006 Feb; 190(2):485-96; discussion 497-8. PubMed ID: 17001874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of recent genetic findings in Parkinson's disease.
    Klein C; Lohmann-Hedrich K
    Curr Opin Neurol; 2007 Aug; 20(4):453-64. PubMed ID: 17620882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular pathogenesis of Parkinson disease: insights from genetic studies.
    Gasser T
    Expert Rev Mol Med; 2009 Jul; 11():e22. PubMed ID: 19631006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular genetic pathways in Parkinson's disease: a review.
    Jain S; Wood NW; Healy DG
    Clin Sci (Lond); 2005 Oct; 109(4):355-64. PubMed ID: 16171459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pathogenesis of sporadic Parkinson's disease: contribution of genetic and environmental risk factors].
    Takahashi R; Kawamata J; Takeuchi H
    Rinsho Shinkeigaku; 2009 Nov; 49(11):885-7. PubMed ID: 20030238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease.
    Vitte J; Traver S; Maués De Paula A; Lesage S; Rovelli G; Corti O; Duyckaerts C; Brice A
    J Neuropathol Exp Neurol; 2010 Sep; 69(9):959-72. PubMed ID: 20720502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synaptic dysfunction in Parkinson's disease.
    Picconi B; Piccoli G; Calabresi P
    Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications.
    Butcher NJ; Kiehl TR; Hazrati LN; Chow EW; Rogaeva E; Lang AE; Bassett AS
    JAMA Neurol; 2013 Nov; 70(11):1359-66. PubMed ID: 24018986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LRRK2 and neurodegeneration.
    Santpere G; Ferrer I
    Acta Neuropathol; 2009 Mar; 117(3):227-46. PubMed ID: 19142648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. α-synuclein promotes neuroprotection through NF-κB-mediated transcriptional regulation of protein kinase Cδ.
    Aoki R; Li YR
    Sci Signal; 2011 Oct; 4(195):jc6. PubMed ID: 22009151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
    Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
    Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptional mutagenesis by 8-oxodG in α-synuclein aggregation and the pathogenesis of Parkinson's disease.
    Basu S; Je G; Kim YS
    Exp Mol Med; 2015 Aug; 47(8):e179. PubMed ID: 26315598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients.
    Chiba-Falek O; Lopez GJ; Nussbaum RL
    Mov Disord; 2006 Oct; 21(10):1703-8. PubMed ID: 16795004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
    Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
    Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
    Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
    Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are genetic and sporadic Parkinson's disease patients equally susceptible to develop dementia?
    Inzelberg R; Polyniki A
    J Neurol Sci; 2010 Feb; 289(1-2):23-6. PubMed ID: 19740488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
    Conway KA; Harper JD; Lansbury PT
    Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pathogenesis of Parkinson's disease: implications from familial Parkinson's disease].
    Iwatsubo T; Ito G; Takatori S; Hannno Y; Kuwahara T
    Rinsho Shinkeigaku; 2005 Nov; 45(11):899-901. PubMed ID: 16447757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pathological mechanisms of Parkinson's disease].
    Matsui H; Takahashi R
    Brain Nerve; 2009 Apr; 61(4):441-6. PubMed ID: 19378814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.